{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:25:05Z","timestamp":1762867505603},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Vancouver Coastal Health Research Institute Team Grant Award"},{"DOI":"10.13039\/100014823","name":"VGH & UBC Hospital Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","ijdp.org","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.drugpo.2018.06.019","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:43:24Z","timestamp":1532393004000},"page":"76-84","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada"],"prefix":"10.1016","volume":"59","author":[{"given":"Susan","family":"Nouch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabab","family":"Elbaharia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nic","family":"Bacani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Kason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Kleban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Knebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2018.06.019_bib0005","series-title":"HCV guidance: Recommendations for testing, managing, and treating hepatitis C","author":"AASLD-IDSA","year":"2018"},{"issue":"September (8)","key":"10.1016\/j.drugpo.2018.06.019_bib0010","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/liv.12370","article-title":"Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents","volume":"34","author":"Alavi","year":"2014","journal-title":"Liver International"},{"issue":"July (9)","key":"10.1016\/j.drugpo.2018.06.019_bib0015","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10826084.2016.1161054","article-title":"Clinicians\u2019 views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs","volume":"51","author":"Asher","year":"2016","journal-title":"Substance Use & Misuse"},{"issue":"September (9)","key":"10.1016\/j.drugpo.2018.06.019_bib0020","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/MEG.0000000000000150","article-title":"Delivery of treatment for hepatitis C virus infection in the primary care setting","volume":"26","author":"Baker","year":"2014","journal-title":"European Journal of Gastroenterology & Hepatology [Internet]"},{"issue":"August (3)","key":"10.1016\/j.drugpo.2018.06.019_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Annals of Internal Medicine (American College of Physicians)"},{"issue":"March (10)","key":"10.1016\/j.drugpo.2018.06.019_bib0030","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jvh.12711","article-title":"Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study","volume":"24","author":"Boglione","year":"2017","journal-title":"Journal of Viral Hepatitis"},{"issue":"December (617)","key":"10.1016\/j.drugpo.2018.06.019_bib0035","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3399\/bjgp13X675421","article-title":"Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care?","volume":"63","author":"Brew","year":"2013","journal-title":"British Journal of General Practice"},{"issue":"April","key":"10.1016\/j.drugpo.2018.06.019_bib0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jsat.2016.12.014","article-title":"Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program","volume":"75","author":"Butner","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"January (61)","key":"10.1016\/j.drugpo.2018.06.019_bib0045","first-page":"S45","article-title":"Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?","volume":"23","author":"Christensen","year":"2018","journal-title":"Addiction"},{"issue":"February (2)","key":"10.1016\/j.drugpo.2018.06.019_bib0050","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"issue":"December (12)","key":"10.1016\/j.drugpo.2018.06.019_bib0055","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Global Health"},{"issue":"Nov (9)","key":"10.1016\/j.drugpo.2018.06.019_bib0060","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: A randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Annals of Internal Medicine (American College of Physicians)"},{"issue":"April","key":"10.1016\/j.drugpo.2018.06.019_bib0065","article-title":"EASL recommendations on treatment of hepatitis C 2018","author":"European Association for the Study of the Liver","year":"2018","journal-title":"Journal of Hepatology"},{"issue":"April (4)","key":"10.1016\/j.drugpo.2018.06.019_bib0070","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1111\/j.1365-2893.2010.01370.x","article-title":"Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia","volume":"18","author":"Grebely","year":"2011","journal-title":"Journal of Viral Hepatitis (Blackwell Publishing Ltd.)"},{"key":"10.1016\/j.drugpo.2018.06.019_bib0075","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.drugpo.2015.07.005","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"26","author":"Grebely","year":"2015","journal-title":"The International Journal on Drug Policy"},{"issue":"January (5)","key":"10.1016\/j.drugpo.2018.06.019_bib0080","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial","author":"Grebely","year":"2018","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"January (1)","key":"10.1016\/j.drugpo.2018.06.019_bib0085","article-title":"Clinical trial: A primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C","author":"Jack","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"March (3)","key":"10.1016\/j.drugpo.2018.06.019_bib0090","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jhep.2016.10.028","article-title":"Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada","volume":"66","author":"Janjua","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"September (5)","key":"10.1016\/j.drugpo.2018.06.019_bib0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M17-0118","article-title":"Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: A nonrandomized clinical trial","volume":"167","author":"Kattakuzhy","year":"2017","journal-title":"Annals of Internal Medicine"},{"issue":"August (2)","key":"10.1016\/j.drugpo.2018.06.019_bib0100","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2015.03.029","article-title":"Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine","volume":"63","author":"Lalezari","year":"2015","journal-title":"Journal of Hepatology"},{"issue":"December (4)","key":"10.1016\/j.drugpo.2018.06.019_bib0105","first-page":"310","article-title":"Hepatitis C virus: A review of treatment guidelines, cost-effectiveness, and access to therapy","volume":"4","author":"Lynch","year":"2016","journal-title":"Journal of Clinical and Translational Hepatology (Xia & He Publishing Inc.)"},{"issue":"Oct (4)","key":"10.1016\/j.drugpo.2018.06.019_bib0110","doi-asserted-by":"crossref","first-page":"E605","DOI":"10.9778\/cmajo.20160008","article-title":"Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: A descriptive study","volume":"4","author":"Marshall","year":"2016","journal-title":"CMAJ Open (Canadian Medical Association)"},{"issue":"October (3)","key":"10.1016\/j.drugpo.2018.06.019_bib0115","article-title":"Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe","author":"Marshall","year":"2017","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"January (1)","key":"10.1016\/j.drugpo.2018.06.019_bib0120","first-page":"49","article-title":"Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations","volume":"55","author":"Martin","year":"2012","journal-title":"Hepatology (Wiley Subscription Services, Inc., A Wiley Company)"},{"issue":"November (5)","key":"10.1016\/j.drugpo.2018.06.019_bib0125","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"issue":"June (47)","key":"10.1016\/j.drugpo.2018.06.019_bib0130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugpo.2017.05.025","article-title":"Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada","volume":"12","author":"Mason","year":"2017","journal-title":"International Journal of Drug Policy"},{"issue":"June","key":"10.1016\/j.drugpo.2018.06.019_bib0135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.drugpo.2017.05.056","article-title":"Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors\u2019 Health Network","volume":"47","author":"Morris","year":"2017","journal-title":"International Journal of Drug Policy"},{"issue":"April (4)","key":"10.1016\/j.drugpo.2018.06.019_bib0140","first-page":"381","article-title":"The burden of hepatitis C virus infection is growing: A Canadian population-based study of hospitalizations from 1994 to 2004","volume":"22","author":"Myers","year":"2008","journal-title":"Canadian Journal of Gastroenterology and Hepatology"},{"issue":"May (5)","key":"10.1016\/j.drugpo.2018.06.019_bib0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1155\/2014\/317623","article-title":"Burden of disease and cost of chronic hepatitis C infection in Canada","volume":"28","author":"Myers","year":"2014","journal-title":"Canadian Journal of Gastroenterology and Hepatology (Hindawi Limited)"},{"issue":"August (9791)","key":"10.1016\/j.drugpo.2018.06.019_bib0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"issue":"September","key":"10.1016\/j.drugpo.2018.06.019_bib0155","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","article-title":"High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic","volume":"47","author":"Norton","year":"2017","journal-title":"International Journal of Drug Policy"},{"issue":"October (7)","key":"10.1016\/j.drugpo.2018.06.019_bib0160","first-page":"889","article-title":"Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection","volume":"165","author":"Patrick","year":"2001","journal-title":"CMAJ"},{"issue":"June (3)","key":"10.1016\/j.drugpo.2018.06.019_bib0165","article-title":"Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting","author":"Read","year":"2017","journal-title":"International Journal on Drug Policy"},{"issue":"April (395)","key":"10.1016\/j.drugpo.2018.06.019_bib0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtbi.2016.01.030","article-title":"Conditions for eradicating hepatitis C in people who inject drugs: A fibrosis aware model of hepatitis C virus transmission","volume":"21","author":"Rozada","year":"2016","journal-title":"Journal of Theoretical Biology"},{"issue":"June (22)","key":"10.1016\/j.drugpo.2018.06.019_bib0175","doi-asserted-by":"crossref","first-page":"E677","DOI":"10.1503\/cmaj.170453","article-title":"The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver","volume":"190","author":"Shah","year":"2018","journal-title":"CMAJ"},{"issue":"December (24)","key":"10.1016\/j.drugpo.2018.06.019_bib0180","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"issue":"October (5)","key":"10.1016\/j.drugpo.2018.06.019_bib0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/ADM.0000000000000147","article-title":"Primary care-based hepatitis C treatment outcomes with first-generation direct-acting agents","volume":"9","author":"Woodrell","year":"2015","journal-title":"Journal of Addiction Medicine"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395918301816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395918301816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T21:43:04Z","timestamp":1589924584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395918301816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":37,"alternative-id":["S0955395918301816"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2018.06.019","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2018.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}